A kind of oral solid pharmaceutical composition containing dronedarone hydrochloride and preparation method thereof

A technology of dronedarone hydrochloride and a composition, which is applied in the field of oral solid pharmaceutical compositions, can solve problems such as the stability of the solid pharmaceutical composition needs to be investigated, and achieves the effects of improving bioavailability, simple and feasible preparation process and low cost

Active Publication Date: 2016-06-22
PHARMA RES INST OF BENCAO TIANYUAN OF BEIJING
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Coupled with the hydrophilic polymer polyvinylpyrrolidone, the stability of the solid pharmaceutical composition remains to be investigated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of oral solid pharmaceutical composition containing dronedarone hydrochloride and preparation method thereof
  • A kind of oral solid pharmaceutical composition containing dronedarone hydrochloride and preparation method thereof
  • A kind of oral solid pharmaceutical composition containing dronedarone hydrochloride and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] According to the test method of "the maintenance test of the active ingredient itself in the pH6.7 solution" provided by the patent CN1091593C, an experiment was designed to investigate the solubility of poloxamer 407 and hydroxypropyl methylcellulose to dronedarone hydrochloride. influences.

[0033] A 2 mg / ml solution of dronedarone hydrochloride was prepared in a pH 4.5 phosphate buffer solution at 37° C. for 2 hours, and filtered through a 0.8 μm filter membrane. The active ingredients in the solution were measured by UV spectroscopy, and the dissolved amount of the main drug in each sample was calculated. The specific results are shown in Table 2.

[0034] The dissolved amount of dronedarone hydrochloride in pH4.5 phosphate buffer solution of table 2

[0035] sample

Dissolution percentage %

Dronedarone Hydrochloride

74.6

Dronedarone Hydrochloride + 10% Poloxamer 407

73.9

Dronedarone Hydrochloride + 10% Hydroxypropyl Methyl...

Embodiment 2

[0043]

[0044] Preparation Process:

[0045] Prescriptions A to D all adopt the wet granulation process; mix micronized dronedarone hydrochloride, hydroxypropyl methylcellulose, lactose, and starch evenly, use 50% ethanol to make soft materials, and make wet granules through a 18-mesh sieve. After drying, 20-mesh sieve is used for sizing, and crospovidone, silicon dioxide and magnesium stearate are added externally, mixed evenly, and compressed into tablets.

[0046] With a concentration of 15% Opadry 85GII68918 aqueous solution as the coating solution, the sample cores of the prescriptions A to D in Example 2 were coated to obtain a self-made sample, which was dissolved together with the original preparation in Appendix XC of Part Two of the Chinese Pharmacopoeia 2010 Edition In the second method of the degree measurement method, the dissolution medium is 1000mLpH4.5PBS, the rotation speed is 75r / min, and UV is measured under the conditions of 10, 15, 30, 45, 60, 90, and ...

Embodiment 3

[0049]

[0050] Preparation Process:

[0051] Prescriptions E and F: mix micronized dronedarone hydrochloride, hydroxypropyl methylcellulose, lactose, and starch evenly, use 30% ethanol to make soft materials, and make wet granules through a 18-mesh sieve. After drying, 20-mesh sieve is sized, and crospovidone, silicon dioxide and magnesium stearate are added externally, and mixed evenly. Prescription E prepares granules and packs them separately. The granules prepared by formulation F were filled into capsules.

[0052] The prescription E granule adopts the second method in the dissolution test method of the second appendix XC of the "Chinese Pharmacopoeia" 2010 edition, and the prescription F capsule adopts the first method in the dissolution test method of the second appendix XC of the "Chinese Pharmacopoeia" 2010 edition. The dissolution medium is 1000mLpH4.5PBS, rotating speed 75r / min, UV measurement under the conditions of 10, 15, 30, 45, 60, 90, 120min respectively...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to an oral solid medicinal composition, which is characterized by comprising pelletized dronedarone hydrochloride and hydrophilic gel matrix type slow release material hydroxypropyl methyl cellulose, wherein the pelletized dronedarone hydrochloride and hydrophilic gel matrix type slow release material hydroxypropyl methyl cellulose are selectively combined with one or more medicinal excipients. The oral solid medicinal composition is mainly used for treating arrhythmia.

Description

technical field [0001] The invention provides an oral solid pharmaceutical composition, which contains micronized dronedarone hydrochloride and hydroxypropyl methylcellulose, a hydrophilic gel matrix sustained-release material, combined with one or more pharmaceutical excipients. Background technique [0002] The chemical name of Dronedarone is N-2-n-butyl-3-[4-(3-di-n-butyl-aminopropoxy)benzoyl]-5-methylsulfabenzofuran , the molecular formula is C 31 h 44 N 2 o 5 S, the molecular weight is 556.765. [0003] Dronedarone Hydrochloride Tablets is an antiarrhythmic drug developed by Sanofi-Aventis for the treatment of patients with paroxysmal or persistent atrial fibrillation or atrial flutter. This product is a benzofuran derivative without iodine. Its structure and characteristics are similar to those of amiodarone, and its lipophilicity is low. It not only maintains the curative effect of amiodarone, but also has no adverse reactions of amiodarone. ~ 2 days, easy to ad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61K31/343A61K47/38A61P9/06
Inventor 孙学伟顾群肖万宏邵波徐春霞
Owner PHARMA RES INST OF BENCAO TIANYUAN OF BEIJING
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap